О целесообразности назначения тиопропиума бромида при некоторых вариантах бронхиальной астмы
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Авдеев С.В. Применение тиотропия бромида при бронхиальной астме. Справ. поликлин. врача. 2008; 10: 24–8.
2. Синопальников А.И. Тиотропия бромид – новый антихолинергический препарат длительного действия. РМЖ. 2003; 11 (22): 1256–61.
3. Фисенко В.П. Тиотропия бромид (спирива) – новый М-холиноблокатор для лечения хронических обструктивных болезней легких. Пульмонология. 2003; 4: 100–4.
4. Чучалин А.Г. Тяжелая бронхиальная астма. РМЖ 2000; 8 (12): 482–6.
5. Цой А.Н. Спирива: новое средство терапии хронической обструктивной болезни легких. Cons. Med. 2003; 5 (10): 3–6.
6. Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs 2001; 10: 733–40.
7. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000; 117 (2 Suppl.): 63–8.
8. Disse B, Reichi R, Speck G et al. A novel long-acting anticholinergic bronchodilator. Life Sci 1993; 52: 537–44.
9. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–40.
10. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–24.
11. Vincken W, van Noord JA, Greethorst AP et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiptropium. Eur Respir J 2002; 19: 209–16.
12. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967–75.
13. Hansel TT, Barnes PJ. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Tod 2002; 38: 585–600.
14. Leusch A, Eichhorn B, Muller G et al. Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. Biopharm Drug Dispos 2001; 22: 199–212.
15. van Noord JA, Smeets JJ, Custers FL et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 639–44.
16. Donohue JF, van Noord JA, Babeman ED et al. A 6-month, placebo-controlled comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55.
17. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123: 1441–9.
18. Magnussen H, Bugnas B, van Noord J еt al. Respir Med J 2008; 102: 50–6.
19. Fabbri LM, Romagnoli M, Corbetta L et al., Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease, Am J Respir Crit Care Med 2003; 167: 418–24.
20. Lanes SF, Garrett JE, Wentworth CE et al., The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials. Chest 1998; 114: 365–72.
21. Rodrigo G, Rodrigo C, Burschtin O. A meta-analysis of the effect of ipratropium bromide in adults with acute asthma. Am J Med 1999; 107: 363–70.
22. Israel E, Chinchilli VM, Ford J et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505–12.
23. Celli BR, MacNee. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (6): 932–46.
24. Vermeire PA, Pride NB. A «Splitting» look at chronic nonspecific lung disease (CNSLD): common features but diverse pathogenesis. Eur Respir J 1991; 4: 490–6.
25. Wenzel SE, Schwartz LB, Langmack LE et al., Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001–8.
26. Saetta M, Di Stefano A, Maestrelli P et al., Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646–52.
27. Kesten S, Rebuck AS. Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest 1994; 105: 1042–5.
28. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53: 129–36.
29. Magnussen H, Richter K, Taube C. Are chronic obstructive pulmonary disease (COPD) and asthma different diseases. Clin Exp Allergy 1998; 28 (Suppl. 5): 187–94.
30. Tashkin D, Kesten S. Long term treatment benefits with tiotropium in COPD patients with and without acute bronchodilator responses. Chest 2003; 123: 1441–9.
31. Tashkin DP, Celli B, Senn S et al. for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
32. Decramer M, Celli B, Tashkin DP et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004; 1: 303–12.
33. Tashkin DP, Celli B, Decramer M et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31: 742–50.
2. Синопальников А.И. Тиотропия бромид – новый антихолинергический препарат длительного действия. РМЖ. 2003; 11 (22): 1256–61.
3. Фисенко В.П. Тиотропия бромид (спирива) – новый М-холиноблокатор для лечения хронических обструктивных болезней легких. Пульмонология. 2003; 4: 100–4.
4. Чучалин А.Г. Тяжелая бронхиальная астма. РМЖ 2000; 8 (12): 482–6.
5. Цой А.Н. Спирива: новое средство терапии хронической обструктивной болезни легких. Cons. Med. 2003; 5 (10): 3–6.
6. Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs 2001; 10: 733–40.
7. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000; 117 (2 Suppl.): 63–8.
8. Disse B, Reichi R, Speck G et al. A novel long-acting anticholinergic bronchodilator. Life Sci 1993; 52: 537–44.
9. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–40.
10. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–24.
11. Vincken W, van Noord JA, Greethorst AP et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiptropium. Eur Respir J 2002; 19: 209–16.
12. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967–75.
13. Hansel TT, Barnes PJ. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Tod 2002; 38: 585–600.
14. Leusch A, Eichhorn B, Muller G et al. Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. Biopharm Drug Dispos 2001; 22: 199–212.
15. van Noord JA, Smeets JJ, Custers FL et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 639–44.
16. Donohue JF, van Noord JA, Babeman ED et al. A 6-month, placebo-controlled comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55.
17. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123: 1441–9.
18. Magnussen H, Bugnas B, van Noord J еt al. Respir Med J 2008; 102: 50–6.
19. Fabbri LM, Romagnoli M, Corbetta L et al., Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease, Am J Respir Crit Care Med 2003; 167: 418–24.
20. Lanes SF, Garrett JE, Wentworth CE et al., The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials. Chest 1998; 114: 365–72.
21. Rodrigo G, Rodrigo C, Burschtin O. A meta-analysis of the effect of ipratropium bromide in adults with acute asthma. Am J Med 1999; 107: 363–70.
22. Israel E, Chinchilli VM, Ford J et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505–12.
23. Celli BR, MacNee. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (6): 932–46.
24. Vermeire PA, Pride NB. A «Splitting» look at chronic nonspecific lung disease (CNSLD): common features but diverse pathogenesis. Eur Respir J 1991; 4: 490–6.
25. Wenzel SE, Schwartz LB, Langmack LE et al., Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001–8.
26. Saetta M, Di Stefano A, Maestrelli P et al., Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646–52.
27. Kesten S, Rebuck AS. Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest 1994; 105: 1042–5.
28. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53: 129–36.
29. Magnussen H, Richter K, Taube C. Are chronic obstructive pulmonary disease (COPD) and asthma different diseases. Clin Exp Allergy 1998; 28 (Suppl. 5): 187–94.
30. Tashkin D, Kesten S. Long term treatment benefits with tiotropium in COPD patients with and without acute bronchodilator responses. Chest 2003; 123: 1441–9.
31. Tashkin DP, Celli B, Senn S et al. for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
32. Decramer M, Celli B, Tashkin DP et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004; 1: 303–12.
33. Tashkin DP, Celli B, Decramer M et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31: 742–50.
Авторы
Н.П.Княжеская
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.